Two Sigma Investments, LP Chinook Therapeutics, Inc. Transaction History

Two Sigma Investments, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $1.22 Million - $2.53 Million	-65,559 Reduced 42.5%	88,706 $3.41 Million
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $336,664 - $419,071	15,637 Added 11.28%	154,265 $3.57 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $1.53 Million - $2.25 Million	-82,317 Reduced 37.26%	138,628 $3.63 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $46,611 - $62,210	2,662 Added 1.22%	220,945 $4.34 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $2.49 Million - $3.72 Million	197,801 Added 965.73%	218,283 $3.82 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $2.3 Million - $3.19 Million	-191,110 Reduced 90.32%	20,482 $335,000
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $1.21 Million - $1.9 Million	-112,853 Reduced 34.78%	211,592 $3.45 Million
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $2.68 Million - $3.47 Million	233,448 Added 256.54%	324,445 $4.14 Million
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $1 Million - $1.4 Million	73,815 Added 429.61%	90,997 $1.29 Million
Q1 2021 May 17, 2021	SELL	$14.17 - $19.11 $707,763 - $954,506	-49,948 Reduced 74.4%	17,182 $267,000
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $798,847 - $1.4 Million	67,130 New	67,130 $1.07 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.